UPLIFT (ENGOT-ov67/GOG-3048): Results from the Phase 2 Trial of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-Directed Dolaflexin Antibody-Drug Conjugate (ADC) in Platinum-Resistant Ovarian Cancer (PROC)


congress.esgo.org
Declaration of Interest

Consulting/Advisory: ImmunoGen, Seagen, Akesobio, EISAI, GSK, AstraZeneca, Mersana Therapeutics, eTheRNA immunotherapies NV, Kartos

Travel Expenses: Roche, Genmab, Amgen

Educational fees: Kartos, MSD, Medscape Oncology, TouchIME

Functions in societies: President of ESGO; Chair of ENGOT Early Drug Development Network
Background

• Effective and well-tolerated treatments for Platinum-Resistant Ovarian Cancer (PROC) remain an unmet medical need.

• Standard of care single-agent chemotherapy has limited efficacy, with response rates at ~12%¹.

• NaPi2b is broadly expressed in solid tumors, including high-grade serous epithelial ovarian cancer*, with expression on healthy type II pneumocytes in the lung, but limited expression in other healthy tissue²,³.

• **Upifitamab rilsodotin (UpRi; XMT-1536)** is a NaPi2b-directed Dolaflexin ADC designed to minimize the common toxicities associated with ADCs (peripheral neuropathy, neutropenia, ocular toxicity).

**Antibody:** Humanized monoclonal anti-SLC34A2 (NaPi2b)

**Linker:** Polymer scaffold; Stochastic cysteine conjugation

**Payload:** AF-HPA - controlled bystander effect; highly potent anti-tubulin inhibitor selectively toxic to rapidly dividing cells

**Drug-to-Antibody Ratio:** Heterogeneous; ~10

---


* Includes fallopian tube and primary peritoneal cancers; NaPi2b, sodium dependent phosphate transport protein; ADC, antibody drug conjugate

---

**UPLIFT (ENGOT-ov67 / GOG-3048)** was a global, single-arm Phase 2 Trial evaluating UpRi in adult patients with platinum-resistant high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancers.
UPLIFT (ENGOT-ov67/GOG-3048): Study Design

**Patient Population**
- HGSOC\(^a\) progressing after standard treatments; measurable disease per RECIST v1.1; ECOG PS 0 or 1; enrolling regardless of NaPi2b expression

**Key Inclusion Criteria**
- Platinum-resistant\(^b\) ovarian cancer
- 1–4 prior lines of therapy
- Grade ≤2 peripheral neuropathy
- Available archived or fresh tissue for retrospective NaPi2b evaluation

**Key Exclusion Criteria**
- 1–2 prior lines AND bevacizumab-naive
- Primary platinum-refractory disease

**UpRi** 36 mg/m\(^2\) up to max 80 mg; IV Q4W

**Primary Endpoint**
- Confirmed INV-assessed ORR in NaPi2b-positive (TPS ≥75)

**Secondary Endpoints**
- Confirmed INV-assessed ORR in overall population
- Confirmed ORR by BICR in the NaPi2b positive and in the ITT population
- INV-assessed DOR in the NaPi2b positive population
- Safety

\(^a\) HGSOC including fallopian tube and primary peritoneal cancer.  
\(^b\) Platinum-resistant is defined as disease that has progressed within 6 months of last dose of platinum.

DOR, duration of response; ECOG, Eastern Cooperative Oncology Group; HGSOC, high-grade serous ovarian cancer; IV, intravenous; NaPi2b, sodium-dependent phosphate transport protein 2B; ORR, overall response rate; q4w, every 4 weeks; RECIST, Response Evaluation Criteria in Solid Tumors; UpRi, upifitamab rilsodotin; TPS, Tumor Proportion Score.
### Patient Demographics and Disease Characteristics

<table>
<thead>
<tr>
<th>NaPi2b Positive (N=141)</th>
<th>ITT Population (N=268)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Median Age (years)</strong></td>
<td>60.0</td>
</tr>
<tr>
<td><strong>Median Baseline BSA, m² (min, max)</strong></td>
<td>1.740 (1.38, 2.43)</td>
</tr>
<tr>
<td><strong>Baseline ECOG Performance Status</strong></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>73 (51.8%)</td>
</tr>
<tr>
<td>1</td>
<td>68 (48.2%)</td>
</tr>
<tr>
<td><strong>Central NaPi2b Expression TPS</strong></td>
<td></td>
</tr>
<tr>
<td>Negative [TPS&lt;75]</td>
<td>0</td>
</tr>
<tr>
<td>Positive [TPS≥75]</td>
<td>141 (100.0%)</td>
</tr>
<tr>
<td>NDa</td>
<td>0</td>
</tr>
<tr>
<td><strong>Median Time Since Initial Diagnosis (mos)</strong></td>
<td>32.88</td>
</tr>
<tr>
<td><strong>Prior Lines of Anti-Cancer Therapy</strong></td>
<td></td>
</tr>
<tr>
<td>1-2</td>
<td>46 (32.6%)</td>
</tr>
<tr>
<td>3</td>
<td>47 (33.3%)</td>
</tr>
<tr>
<td>4</td>
<td>48 (34.0%)</td>
</tr>
<tr>
<td><strong>Number of Lines of Prior Therapy in a Platinum-Resistant Setting</strong></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>66 (46.8%)</td>
</tr>
<tr>
<td>1-2</td>
<td>70 (49.6%)</td>
</tr>
<tr>
<td>3</td>
<td>5 (3.5%)</td>
</tr>
<tr>
<td><strong>Patients with Prior Bev/Bev Biosimilar</strong></td>
<td>117 (83.0%)</td>
</tr>
<tr>
<td><strong>Patients with Prior PARPi</strong></td>
<td>97 (68.8%)</td>
</tr>
<tr>
<td><strong>Median Duration of Most Recent PFIb (mos)</strong></td>
<td>3.52</td>
</tr>
</tbody>
</table>

- 52.6% (N=141) of patients determined to be NaPi2b positive (TPS≥75)
- Approximately 1/3 of patients had 4 prior lines of therapy
- More than half of patients had at least 1 prior therapy in the PROC setting
- 83% and 69% of patients had prior bev or prior PARPi, respectively

---

a NaPi2b expression not determined; b Platinum-free interval defined as the time between the last cycle of most recent platinum-containing regimen and evidence of disease progression; determined from treatment dates and/or clinic notes.

BSA, body surface area; ECOG, Eastern Cooperative Oncology Group; NaPi2b, sodium-dependent phosphate transport protein 2B; TPS, tumor proportion score; PARPi, poly (ADP-ribose) polymerase inhibitor.
Investigator-Assessed Objective Response Rate in NaPi2b Positive, NaPi2b Negative and ITT Population

<table>
<thead>
<tr>
<th></th>
<th>NaPi2-Positive Population (TPS ≥75)</th>
<th>NaPi2b-low Population (TPS &lt;75)</th>
<th>ITT Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>141</td>
<td>127</td>
<td>268</td>
</tr>
<tr>
<td>ORRa, n (%)</td>
<td>22 (15.6%)</td>
<td>13 (10.2%)</td>
<td>35 (13.1%)</td>
</tr>
<tr>
<td></td>
<td>10.0%, 22.7%</td>
<td>5.6%, 16.9%</td>
<td>9.3%, 17.7%</td>
</tr>
<tr>
<td>CR, n (%)</td>
<td>2 (1.4%)</td>
<td>1 (0.8%)</td>
<td>3 (1.1%)</td>
</tr>
<tr>
<td>PR, n (%)</td>
<td>20 (14.2%)</td>
<td>12 (9.4%)</td>
<td>32 (11.9%)</td>
</tr>
<tr>
<td>DCRb</td>
<td>93 (66.0%)</td>
<td>64 (50.4%)</td>
<td>157 (58.6%)</td>
</tr>
</tbody>
</table>

Biomarker did not appear to enrich for response

Data cut: May 31, 2023

aORR is determined by investigator radiologic review and defined as the proportion of patients who achieve a confirmed CR or PR per RECIST v1.1. The exact two-sided 95% CI is calculated based on binomial distribution using the Clopper-Pearson method; bDCR is defined as the proportion of patients who achieve a confirmed CR, PR, or SD.
Investigator-Assessed Duration of Response: NaPi2b-Positive Population (N=22) and ITT (N=35)

Data cut: May 31, 2023

DOR, duration of response; NaPi2b, sodium-dependent phosphate transport protein 2B; NR, not reached; ITT, intent to treat
## Overall Summary of TEAEs Leading to Discontinuation/Delay/Hold

<table>
<thead>
<tr>
<th>Event</th>
<th>UPLIFT Safety Population (ITT; N=268)</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>268</td>
</tr>
<tr>
<td>Any TEAE Leading to Drug Discontinuation</td>
<td>70 (26.1%)</td>
</tr>
<tr>
<td>Any TEAE Leading to Dose Delay/Hold</td>
<td>110 (41.0%)</td>
</tr>
<tr>
<td>Any TEAE Leading to Dose Reduction</td>
<td>72 (26.9%)</td>
</tr>
<tr>
<td>Any TEAE Leading to Death(^a)</td>
<td>15 (5.6%)</td>
</tr>
</tbody>
</table>

*Data cut: May 31, 2023*

\(^a\)TEAEs leading to death: Intracranial hemorrhage (N=3); sepsis (N=3), sudden death (N=2), and following events were seen in one participant each: tumor hemorrhage, pulmonary hemorrhage, acute MI, acute pulmonary edema, lymphangitic carcinomatosis, peritoneal perforation, circulatory shock.
TRAEs Observed in ≥15% of Patients (N=268)

- AST increased
- Nausea
- Platelet count decreased*
- Fatigue
- Anaemia
- Pyrexia
- ALT increased
- Blood ALP increased
- Blood LDH increased
- Proteinuria
- Vomiting
- Asthenia
- Decreased appetite
- Diarrhea
- Headache
- Constipation

- Gr3+ Gr1-2

- G3 peripheral neuropathy and neutropenia occurred in <1%; no G3+ ocular toxicity
- Pneumonitis occurred in 9.7% of patients, 0.7% G3 (no G4 or G5); believed to be on-target toxicity due to NaPi2b expression on Type II pneumocytes in the lungs
- Based on aggregate analysis of bleeding cases, treatment emergent G3+ hemorrhage occurred in 5.6% of patients, including 5 G5 (fatal) cases
- Hypothesize that the high-DAR sub-population within UpRi disproportionately delivered payload to endothelial cells resulting in off-target toxicities, including thrombocytopenia and bleeding

Data cut: May 31, 2023
* Includes thrombocytopenia
Dolaflexin’s Heterogeneity and High-DAR Sub-Populations are Believed to Have Contributed to Off-Target Toxicities

Dolaflexin Heterogeneous ADC population – an ADC sub-population mixture

- A heterogeneous ADC mixture, UpRi is composed of ADCs with a wide range of DARs that average a DAR of ~10
- Sub-population fractionation of a Dolaflexin ADC (upper right) suggests reduced tumor-specific delivery at the higher DAR compared to lower DAR
- Hypothesized that the high-DAR subpopulation may have reduced UpRi’s efficacy while also increasing toxicity, including potentially thrombocytopenia and bleeding

* As measured by hydrophobic interaction chromatography, 280 nanometers
Conclusion

UPLIFT failed to meet its primary endpoint, confirmed ORR in NaPi2b-positive patients, criterion (lower limit of 95% CI >12%)

Investigator-assessed efficacy showed modest anti-tumor activity:

- Observed ORR in NaPi2b-positive was 15.6% (95% CI 10.0, 22.7)
- Observed ORR in ITT was 13.1% (95% CI 9.3, 17.7)
- Biomarker did not appear to enrich for response
- Durable response observed in NaPi2b positive responders: DOR 7.4 months (95% CI 4.2, NR)

Safety:

- Most common TRAEs included transient AST increase, nausea, platelet count decrease/thrombocytopenia, fatigue, and anemia
- G3+ bleeding, including fatal cases observed; hypothesize that UpRi's high-DAR sub-populations disproportionately delivered payload to endothelial cells, resulting in off-target toxicities
- Generally low grade pneumonitis observed; believed to be on-target toxicity due to NaPi2b expression on Type II pneumocytes in the lungs

Based on the efficacy not meeting prespecified primary endpoint criterion, the sponsor discontinued the development of UpRi
Acknowledgments

Thank you to the patients and their families participating in this study and to my fellow investigators and their research staff

University Hospital Innsbruck, Austria
Université Paul Cézanne, France
University of California – Irvine, CA
University of Virginia - Emily Couric, VA
University of Washington, WA

Additional Sites

Chris O’Brien Lifehouse, Australia
Peter MacCallum Center, Australia
Blacktown Hospital, Australia

McGill University, Canada
British Columbia Cancer Agency, Canada

START – Midwest, MI, USA
Atrium Health - Levine Cancer Center, NC, USA
Mount Sinai, NY, USA
University of Pittsburgh, PA, USA
Allegheny Health Network, PA, USA
Sarah Cannon Research Institute, TN, USA
START, TX, USA
Mary Crowley Cancer Research Center, TX, USA
University of Utah, UT, USA
THANK YOU